| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gout | 60 | 2022 | 75 | 9.770 |
Why?
|
| Gout Suppressants | 28 | 2022 | 35 | 5.610 |
Why?
|
| Hyperuricemia | 16 | 2022 | 24 | 4.330 |
Why?
|
| Allopurinol | 18 | 2022 | 77 | 3.690 |
Why?
|
| Uric Acid | 41 | 2022 | 136 | 3.620 |
Why?
|
| Ribose-Phosphate Pyrophosphokinase | 53 | 2003 | 53 | 3.610 |
Why?
|
| Thiazoles | 15 | 2022 | 127 | 2.910 |
Why?
|
| Febuxostat | 19 | 2022 | 19 | 1.620 |
Why?
|
| Xanthine Oxidase | 8 | 2013 | 25 | 1.570 |
Why?
|
| Urate Oxidase | 9 | 2014 | 11 | 1.560 |
Why?
|
| Phosphotransferases | 33 | 1989 | 65 | 1.530 |
Why?
|
| Uricosuric Agents | 6 | 2017 | 11 | 1.510 |
Why?
|
| Purines | 20 | 2016 | 93 | 1.490 |
Why?
|
| Enzyme Inhibitors | 7 | 2013 | 644 | 1.250 |
Why?
|
| Polyethylene Glycols | 8 | 2014 | 360 | 1.250 |
Why?
|
| Coronary Stenosis | 2 | 2015 | 39 | 0.960 |
Why?
|
| Pyrimidines | 6 | 2016 | 371 | 0.860 |
Why?
|
| Phosphoribosyl Pyrophosphate | 19 | 2001 | 19 | 0.850 |
Why?
|
| Humans | 167 | 2023 | 89864 | 0.740 |
Why?
|
| Purine Nucleotides | 19 | 1999 | 22 | 0.730 |
Why?
|
| Risk Reduction Behavior | 2 | 2014 | 97 | 0.730 |
Why?
|
| X Chromosome | 12 | 1999 | 153 | 0.710 |
Why?
|
| Cardiovascular Diseases | 6 | 2019 | 716 | 0.710 |
Why?
|
| Respiration, Artificial | 8 | 2010 | 358 | 0.650 |
Why?
|
| Middle Aged | 54 | 2019 | 26103 | 0.640 |
Why?
|
| Chronic Disease | 18 | 2015 | 958 | 0.630 |
Why?
|
| Purine-Pyrimidine Metabolism, Inborn Errors | 14 | 1998 | 14 | 0.630 |
Why?
|
| Male | 79 | 2019 | 42614 | 0.620 |
Why?
|
| Organic Anion Transporters | 3 | 2014 | 26 | 0.610 |
Why?
|
| Aged | 39 | 2019 | 19230 | 0.600 |
Why?
|
| Pentosephosphates | 16 | 1989 | 16 | 0.590 |
Why?
|
| Female | 77 | 2019 | 46529 | 0.570 |
Why?
|
| Echocardiography | 3 | 2019 | 944 | 0.570 |
Why?
|
| Thioglycolates | 1 | 2017 | 2 | 0.570 |
Why?
|
| Whole-Body Irradiation | 2 | 2013 | 66 | 0.540 |
Why?
|
| Isoenzymes | 7 | 2001 | 274 | 0.540 |
Why?
|
| Triazoles | 1 | 2017 | 104 | 0.530 |
Why?
|
| Enzymes, Immobilized | 2 | 2012 | 11 | 0.520 |
Why?
|
| Angina Pectoris | 1 | 2015 | 29 | 0.510 |
Why?
|
| Treatment Outcome | 29 | 2022 | 8264 | 0.510 |
Why?
|
| Severity of Illness Index | 12 | 2019 | 1858 | 0.490 |
Why?
|
| Acute Coronary Syndrome | 1 | 2015 | 30 | 0.490 |
Why?
|
| Transplantation Conditioning | 3 | 2013 | 373 | 0.480 |
Why?
|
| Echocardiography, Stress | 1 | 2014 | 20 | 0.480 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2014 | 94 | 0.460 |
Why?
|
| Fibroblasts | 34 | 1996 | 759 | 0.460 |
Why?
|
| Postmenopause | 1 | 2014 | 102 | 0.460 |
Why?
|
| Adult | 48 | 2019 | 26784 | 0.460 |
Why?
|
| Coronary Artery Disease | 2 | 2018 | 364 | 0.440 |
Why?
|
| Pentostatin | 1 | 2013 | 30 | 0.440 |
Why?
|
| Photopheresis | 1 | 2013 | 12 | 0.440 |
Why?
|
| Electrocardiography | 1 | 2015 | 497 | 0.420 |
Why?
|
| Stroke Volume | 1 | 2015 | 479 | 0.410 |
Why?
|
| Aged, 80 and over | 15 | 2019 | 6779 | 0.410 |
Why?
|
| Ventricular Function, Left | 2 | 2019 | 613 | 0.410 |
Why?
|
| Kinetics | 31 | 2005 | 1534 | 0.410 |
Why?
|
| Clinical Medicine | 1 | 2012 | 34 | 0.400 |
Why?
|
| Diabetes Complications | 1 | 2013 | 171 | 0.400 |
Why?
|
| Dose-Response Relationship, Drug | 14 | 2014 | 1929 | 0.390 |
Why?
|
| Erythrocytes | 21 | 1984 | 254 | 0.380 |
Why?
|
| Hypoxanthine Phosphoribosyltransferase | 13 | 1992 | 36 | 0.380 |
Why?
|
| Cardiac Pacing, Artificial | 2 | 2010 | 103 | 0.380 |
Why?
|
| Double-Blind Method | 11 | 2019 | 1714 | 0.380 |
Why?
|
| Feeding Behavior | 1 | 2014 | 328 | 0.370 |
Why?
|
| Pacemaker, Artificial | 2 | 2010 | 96 | 0.370 |
Why?
|
| Sick Leave | 1 | 2010 | 13 | 0.370 |
Why?
|
| Schools, Medical | 1 | 2012 | 136 | 0.360 |
Why?
|
| Hematologic Neoplasms | 2 | 2013 | 344 | 0.350 |
Why?
|
| Metabolic Syndrome | 2 | 2015 | 123 | 0.350 |
Why?
|
| Point Mutation | 6 | 2003 | 245 | 0.350 |
Why?
|
| Human Development | 1 | 2010 | 7 | 0.350 |
Why?
|
| Physicians, Family | 1 | 2010 | 39 | 0.350 |
Why?
|
| Disability Evaluation | 3 | 2011 | 139 | 0.350 |
Why?
|
| Prospective Studies | 11 | 2019 | 4322 | 0.340 |
Why?
|
| Form Perception | 1 | 2010 | 37 | 0.340 |
Why?
|
| Faculty, Medical | 1 | 2012 | 188 | 0.340 |
Why?
|
| Genetic Linkage | 7 | 1999 | 624 | 0.330 |
Why?
|
| Inflammation | 1 | 2015 | 981 | 0.320 |
Why?
|
| Clinical Competence | 2 | 2015 | 794 | 0.310 |
Why?
|
| Space Perception | 1 | 2010 | 117 | 0.310 |
Why?
|
| Scleroderma, Diffuse | 3 | 2018 | 3 | 0.310 |
Why?
|
| Comorbidity | 5 | 2013 | 952 | 0.300 |
Why?
|
| Kidney Diseases | 3 | 2018 | 320 | 0.300 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2013 | 889 | 0.290 |
Why?
|
| Health Status | 2 | 2009 | 371 | 0.290 |
Why?
|
| Arthritis, Gouty | 2 | 2006 | 4 | 0.290 |
Why?
|
| Computer Graphics | 1 | 2007 | 100 | 0.280 |
Why?
|
| Visual Perception | 1 | 2010 | 326 | 0.270 |
Why?
|
| Chondrocalcinosis | 1 | 2006 | 8 | 0.270 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2014 | 3468 | 0.270 |
Why?
|
| Kidney | 3 | 2013 | 1148 | 0.270 |
Why?
|
| Respiratory Mechanics | 1 | 2007 | 102 | 0.270 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2019 | 222 | 0.260 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2014 | 2414 | 0.260 |
Why?
|
| Monitoring, Physiologic | 1 | 2007 | 265 | 0.250 |
Why?
|
| Xanthine Dehydrogenase | 1 | 2005 | 5 | 0.250 |
Why?
|
| Rheumatology | 3 | 2011 | 35 | 0.250 |
Why?
|
| Young Adult | 10 | 2017 | 6389 | 0.240 |
Why?
|
| Recurrence | 6 | 2016 | 1144 | 0.230 |
Why?
|
| Physicians | 1 | 2012 | 691 | 0.230 |
Why?
|
| Managed Care Programs | 1 | 2004 | 42 | 0.230 |
Why?
|
| Adolescent | 15 | 2017 | 9327 | 0.230 |
Why?
|
| Sexuality | 1 | 2004 | 41 | 0.230 |
Why?
|
| Renal Insufficiency | 2 | 2016 | 98 | 0.230 |
Why?
|
| Quality of Life | 3 | 2009 | 1680 | 0.230 |
Why?
|
| Predictive Value of Tests | 4 | 2018 | 1729 | 0.230 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2004 | 69 | 0.230 |
Why?
|
| Coronary Angiography | 2 | 2015 | 243 | 0.220 |
Why?
|
| Otitis Media | 1 | 2023 | 20 | 0.220 |
Why?
|
| Risk Assessment | 6 | 2019 | 2324 | 0.220 |
Why?
|
| Multivariate Analysis | 3 | 2015 | 983 | 0.220 |
Why?
|
| Area Under Curve | 3 | 2018 | 338 | 0.210 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2020 | 2505 | 0.210 |
Why?
|
| Patient Compliance | 1 | 2004 | 230 | 0.210 |
Why?
|
| Drug Resistance | 7 | 2014 | 232 | 0.210 |
Why?
|
| Methylprednisolone | 3 | 2011 | 64 | 0.210 |
Why?
|
| Hypergammaglobulinemia | 1 | 2002 | 8 | 0.210 |
Why?
|
| Choroid Diseases | 1 | 2002 | 5 | 0.210 |
Why?
|
| Blood Viscosity | 1 | 2002 | 16 | 0.210 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 3 | 2004 | 54 | 0.200 |
Why?
|
| Plasmapheresis | 1 | 2002 | 25 | 0.200 |
Why?
|
| Heart Transplantation | 1 | 2008 | 728 | 0.200 |
Why?
|
| Choroid | 1 | 2002 | 36 | 0.200 |
Why?
|
| Time Factors | 8 | 2018 | 5357 | 0.200 |
Why?
|
| Follow-Up Studies | 6 | 2018 | 3670 | 0.200 |
Why?
|
| Education, Nursing, Baccalaureate | 1 | 2021 | 3 | 0.200 |
Why?
|
| Students, Nursing | 1 | 2021 | 5 | 0.200 |
Why?
|
| United States | 6 | 2017 | 7094 | 0.200 |
Why?
|
| Arthritis, Rheumatoid | 2 | 2002 | 171 | 0.200 |
Why?
|
| Internet | 1 | 2004 | 323 | 0.200 |
Why?
|
| Treatment Failure | 3 | 2016 | 278 | 0.200 |
Why?
|
| Heart Failure | 2 | 2010 | 1252 | 0.190 |
Why?
|
| Prognosis | 5 | 2019 | 3789 | 0.190 |
Why?
|
| Glomerular Filtration Rate | 3 | 2019 | 277 | 0.190 |
Why?
|
| Motivation | 1 | 2004 | 296 | 0.190 |
Why?
|
| Retinal Vessels | 1 | 2002 | 59 | 0.190 |
Why?
|
| Risk Factors | 5 | 2018 | 5548 | 0.190 |
Why?
|
| Sexual Behavior | 1 | 2004 | 312 | 0.190 |
Why?
|
| Leukemia, Myeloid, Acute | 3 | 2014 | 798 | 0.190 |
Why?
|
| Infant, Newborn | 12 | 2010 | 2498 | 0.190 |
Why?
|
| Retinal Diseases | 1 | 2002 | 90 | 0.190 |
Why?
|
| Survival Rate | 4 | 2017 | 1898 | 0.190 |
Why?
|
| Bone Marrow Transplantation | 2 | 2016 | 283 | 0.180 |
Why?
|
| Child | 15 | 2023 | 7233 | 0.180 |
Why?
|
| Graft vs Host Disease | 3 | 2011 | 358 | 0.180 |
Why?
|
| Emergency Treatment | 1 | 2001 | 45 | 0.180 |
Why?
|
| Deafness | 3 | 1989 | 48 | 0.180 |
Why?
|
| Recombinant Proteins | 4 | 1995 | 1008 | 0.170 |
Why?
|
| Pancreatitis | 3 | 2008 | 86 | 0.170 |
Why?
|
| Glucocorticoids | 3 | 2011 | 357 | 0.170 |
Why?
|
| Parkinson Disease | 1 | 2021 | 150 | 0.170 |
Why?
|
| Reproducibility of Results | 8 | 2015 | 2766 | 0.170 |
Why?
|
| Molecular Sequence Data | 7 | 2001 | 3024 | 0.170 |
Why?
|
| ROC Curve | 3 | 2018 | 778 | 0.170 |
Why?
|
| Cells, Cultured | 17 | 1999 | 2887 | 0.170 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 1998 | 217 | 0.170 |
Why?
|
| Methotrexate | 3 | 2017 | 243 | 0.170 |
Why?
|
| Colchicine | 2 | 2019 | 24 | 0.170 |
Why?
|
| History, 21st Century | 2 | 2012 | 184 | 0.160 |
Why?
|
| Hypertension | 3 | 2019 | 747 | 0.160 |
Why?
|
| Inosine | 5 | 1989 | 19 | 0.160 |
Why?
|
| History, 20th Century | 2 | 2012 | 314 | 0.160 |
Why?
|
| Infant, Premature | 3 | 2010 | 299 | 0.160 |
Why?
|
| Skin | 10 | 2018 | 589 | 0.150 |
Why?
|
| Skin Tests | 1 | 2018 | 44 | 0.150 |
Why?
|
| B-Lymphocytes | 4 | 2008 | 740 | 0.150 |
Why?
|
| Immunosuppressive Agents | 3 | 2017 | 977 | 0.150 |
Why?
|
| Decision Support Techniques | 1 | 2019 | 168 | 0.150 |
Why?
|
| Infant, Premature, Diseases | 2 | 1998 | 77 | 0.150 |
Why?
|
| Drug Administration Schedule | 7 | 2014 | 865 | 0.140 |
Why?
|
| Sesquiterpenes | 2 | 2014 | 12 | 0.140 |
Why?
|
| Sex Factors | 4 | 2012 | 1074 | 0.140 |
Why?
|
| Lymphocytes | 8 | 1996 | 468 | 0.140 |
Why?
|
| Palliative Care | 1 | 2019 | 264 | 0.140 |
Why?
|
| Disease-Free Survival | 3 | 2016 | 1168 | 0.140 |
Why?
|
| Base Sequence | 6 | 1999 | 2329 | 0.140 |
Why?
|
| Biosynthetic Pathways | 1 | 2016 | 10 | 0.140 |
Why?
|
| Remission Induction | 3 | 2014 | 740 | 0.140 |
Why?
|
| Mycophenolic Acid | 1 | 2017 | 84 | 0.140 |
Why?
|
| Obesity | 3 | 2013 | 972 | 0.140 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 260 | 0.140 |
Why?
|
| Respiration | 2 | 1998 | 267 | 0.140 |
Why?
|
| Drug Combinations | 1 | 2017 | 203 | 0.130 |
Why?
|
| Methylthioinosine | 4 | 1992 | 4 | 0.130 |
Why?
|
| Retrospective Studies | 9 | 2019 | 9185 | 0.130 |
Why?
|
| Cyclophosphamide | 1 | 2017 | 301 | 0.130 |
Why?
|
| Lung Compliance | 2 | 2007 | 15 | 0.130 |
Why?
|
| Clinical Trials as Topic | 2 | 2011 | 1134 | 0.130 |
Why?
|
| Intention to Treat Analysis | 2 | 2013 | 72 | 0.130 |
Why?
|
| Multiple Myeloma | 1 | 2020 | 331 | 0.130 |
Why?
|
| Cell Line | 12 | 1993 | 2495 | 0.130 |
Why?
|
| Observer Variation | 2 | 2015 | 614 | 0.130 |
Why?
|
| Gene Expression | 1 | 2000 | 1309 | 0.130 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2014 | 374 | 0.120 |
Why?
|
| Trypsin Inhibitor, Kazal Pancreatic | 3 | 2008 | 5 | 0.120 |
Why?
|
| Osteoarthritis, Hip | 1 | 2015 | 22 | 0.120 |
Why?
|
| Leukocytes, Mononuclear | 1 | 1996 | 206 | 0.120 |
Why?
|
| Chi-Square Distribution | 1 | 2015 | 358 | 0.120 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 2012 | 76 | 0.120 |
Why?
|
| Antibodies, Monoclonal | 3 | 2008 | 1394 | 0.120 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2016 | 153 | 0.120 |
Why?
|
| Practice Guidelines as Topic | 2 | 2015 | 1054 | 0.120 |
Why?
|
| Phenylbutyrates | 1 | 2014 | 9 | 0.120 |
Why?
|
| Mass Spectrometry | 2 | 2013 | 194 | 0.120 |
Why?
|
| Stress, Mechanical | 1 | 2015 | 253 | 0.120 |
Why?
|
| Myocardial Infarction | 1 | 2018 | 380 | 0.120 |
Why?
|
| Salvage Therapy | 2 | 2014 | 230 | 0.120 |
Why?
|
| Cohort Studies | 4 | 2017 | 2886 | 0.120 |
Why?
|
| Benzbromarone | 1 | 2014 | 1 | 0.120 |
Why?
|
| Mutation | 9 | 2008 | 4164 | 0.120 |
Why?
|
| Osteoarthritis, Knee | 1 | 2015 | 66 | 0.120 |
Why?
|
| Animals | 15 | 2015 | 27516 | 0.120 |
Why?
|
| Transcription, Genetic | 1 | 1999 | 1158 | 0.110 |
Why?
|
| Tylenchoidea | 1 | 2013 | 1 | 0.110 |
Why?
|
| Musa | 1 | 2013 | 1 | 0.110 |
Why?
|
| Vasodilator Agents | 1 | 2014 | 145 | 0.110 |
Why?
|
| Piperazines | 2 | 2008 | 283 | 0.110 |
Why?
|
| Liver | 3 | 2011 | 1211 | 0.110 |
Why?
|
| Multimodal Imaging | 1 | 2014 | 111 | 0.110 |
Why?
|
| Disease Resistance | 1 | 2013 | 18 | 0.110 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2014 | 90 | 0.110 |
Why?
|
| Phenols | 1 | 2013 | 41 | 0.110 |
Why?
|
| Benzoates | 1 | 2013 | 33 | 0.110 |
Why?
|
| Chemoradiotherapy | 1 | 2016 | 306 | 0.110 |
Why?
|
| Infusions, Intravenous | 4 | 2014 | 416 | 0.110 |
Why?
|
| Carrier Proteins | 2 | 2008 | 678 | 0.110 |
Why?
|
| Hydrazines | 1 | 2013 | 31 | 0.110 |
Why?
|
| Biomechanical Phenomena | 1 | 2015 | 477 | 0.110 |
Why?
|
| Prednisolone | 2 | 2004 | 40 | 0.110 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 54 | 0.110 |
Why?
|
| Lost to Follow-Up | 1 | 2013 | 15 | 0.110 |
Why?
|
| Plant Diseases | 1 | 2013 | 76 | 0.110 |
Why?
|
| Phosphates | 7 | 1986 | 161 | 0.110 |
Why?
|
| Patient Dropouts | 1 | 2013 | 30 | 0.110 |
Why?
|
| Orthopedic Procedures | 1 | 2015 | 129 | 0.110 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 848 | 0.110 |
Why?
|
| Antibodies | 2 | 2014 | 353 | 0.110 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2015 | 244 | 0.110 |
Why?
|
| Orthopedics | 1 | 2015 | 130 | 0.110 |
Why?
|
| Transplantation, Homologous | 2 | 2013 | 995 | 0.100 |
Why?
|
| Azacitidine | 1 | 2013 | 147 | 0.100 |
Why?
|
| Age Factors | 2 | 2010 | 1880 | 0.100 |
Why?
|
| Antineoplastic Agents | 3 | 2016 | 2328 | 0.100 |
Why?
|
| Pyrazoles | 1 | 2013 | 150 | 0.100 |
Why?
|
| Neoplastic Stem Cells | 1 | 2014 | 162 | 0.100 |
Why?
|
| Infant | 5 | 2011 | 3187 | 0.100 |
Why?
|
| Sirolimus | 1 | 2013 | 162 | 0.100 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2014 | 201 | 0.100 |
Why?
|
| Multiple Sclerosis, Chronic Progressive | 1 | 2012 | 8 | 0.100 |
Why?
|
| North America | 1 | 2012 | 188 | 0.100 |
Why?
|
| Stem Cell Transplantation | 1 | 2013 | 189 | 0.100 |
Why?
|
| Reference Values | 6 | 2004 | 662 | 0.100 |
Why?
|
| Ribosemonophosphates | 5 | 1981 | 5 | 0.100 |
Why?
|
| Neuromyelitis Optica | 1 | 2012 | 22 | 0.100 |
Why?
|
| Glucosephosphate Dehydrogenase Deficiency | 2 | 1981 | 8 | 0.100 |
Why?
|
| Liver Function Tests | 1 | 2011 | 92 | 0.100 |
Why?
|
| Pulmonary Surfactants | 2 | 2004 | 19 | 0.100 |
Why?
|
| Adenosine | 1 | 2014 | 240 | 0.100 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 1 | 2012 | 58 | 0.100 |
Why?
|
| Age Distribution | 1 | 2011 | 199 | 0.090 |
Why?
|
| Cytoprotection | 1 | 2010 | 47 | 0.090 |
Why?
|
| Biomarkers | 3 | 2012 | 1774 | 0.090 |
Why?
|
| Amifostine | 1 | 2010 | 51 | 0.090 |
Why?
|
| Surgeons | 1 | 2015 | 249 | 0.090 |
Why?
|
| Delphi Technique | 2 | 2007 | 101 | 0.090 |
Why?
|
| DNA Mutational Analysis | 2 | 2008 | 529 | 0.090 |
Why?
|
| Proteomics | 1 | 2012 | 232 | 0.090 |
Why?
|
| Architecture | 1 | 2010 | 1 | 0.090 |
Why?
|
| Humanities | 1 | 2010 | 2 | 0.090 |
Why?
|
| Art | 1 | 2010 | 5 | 0.090 |
Why?
|
| Adolescent Development | 1 | 2010 | 21 | 0.090 |
Why?
|
| Morbidity | 1 | 2010 | 149 | 0.080 |
Why?
|
| Science | 1 | 2010 | 34 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2016 | 1350 | 0.080 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2013 | 605 | 0.080 |
Why?
|
| Self Report | 1 | 2011 | 297 | 0.080 |
Why?
|
| Hyperlipidemias | 1 | 2010 | 92 | 0.080 |
Why?
|
| Body Mass Index | 1 | 2013 | 776 | 0.080 |
Why?
|
| Interpersonal Relations | 1 | 2010 | 177 | 0.080 |
Why?
|
| Gastrointestinal Tract | 1 | 2011 | 192 | 0.080 |
Why?
|
| Adenosine Diphosphate | 4 | 1995 | 56 | 0.080 |
Why?
|
| Nuclear Proteins | 2 | 2017 | 727 | 0.080 |
Why?
|
| Self-Assessment | 1 | 2009 | 47 | 0.080 |
Why?
|
| Lymphoma | 1 | 2010 | 266 | 0.080 |
Why?
|
| B-Cell Activating Factor | 1 | 2008 | 5 | 0.080 |
Why?
|
| Myocardial Contraction | 1 | 2010 | 252 | 0.080 |
Why?
|
| Acute Disease | 5 | 2008 | 846 | 0.080 |
Why?
|
| Delayed-Action Preparations | 2 | 2019 | 110 | 0.080 |
Why?
|
| Hypoxanthines | 8 | 1989 | 11 | 0.080 |
Why?
|
| Coronary Vessels | 1 | 2010 | 192 | 0.080 |
Why?
|
| Transplantation, Autologous | 3 | 2016 | 347 | 0.080 |
Why?
|
| Sex Chromosomes | 2 | 1979 | 57 | 0.080 |
Why?
|
| Child Development | 1 | 2010 | 167 | 0.080 |
Why?
|
| Extremities | 2 | 2006 | 173 | 0.070 |
Why?
|
| Child, Preschool | 4 | 2004 | 3765 | 0.070 |
Why?
|
| Drug Discovery | 1 | 2009 | 107 | 0.070 |
Why?
|
| Activities of Daily Living | 1 | 2009 | 205 | 0.070 |
Why?
|
| Amino Acid Sequence | 3 | 2001 | 2063 | 0.070 |
Why?
|
| Molecular Biology | 1 | 2008 | 89 | 0.070 |
Why?
|
| Adenosine Triphosphate | 6 | 1993 | 316 | 0.070 |
Why?
|
| RNA Polymerase III | 2 | 2018 | 8 | 0.070 |
Why?
|
| Pedigree | 7 | 2002 | 971 | 0.070 |
Why?
|
| Chicago | 1 | 2012 | 1431 | 0.070 |
Why?
|
| DNA | 5 | 2002 | 1311 | 0.070 |
Why?
|
| Creatinine | 4 | 2019 | 294 | 0.070 |
Why?
|
| Administration, Oral | 3 | 2004 | 666 | 0.070 |
Why?
|
| Escherichia coli | 3 | 1995 | 607 | 0.070 |
Why?
|
| Pentosyltransferases | 6 | 1979 | 35 | 0.070 |
Why?
|
| Linear Models | 1 | 2008 | 421 | 0.070 |
Why?
|
| Ventilators, Mechanical | 1 | 2007 | 35 | 0.070 |
Why?
|
| Leukemia, Myeloid | 1 | 2008 | 249 | 0.070 |
Why?
|
| Pilot Projects | 3 | 2019 | 871 | 0.070 |
Why?
|
| Metabolism, Inborn Errors | 1 | 1986 | 30 | 0.070 |
Why?
|
| Cytarabine | 3 | 2014 | 219 | 0.070 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2008 | 212 | 0.070 |
Why?
|
| Organic Cation Transport Proteins | 1 | 2006 | 13 | 0.070 |
Why?
|
| Chromosome Mapping | 4 | 1994 | 1074 | 0.070 |
Why?
|
| Odds Ratio | 1 | 2008 | 682 | 0.070 |
Why?
|
| DNA, Complementary | 2 | 1999 | 391 | 0.060 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2010 | 603 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 3 | 2008 | 919 | 0.060 |
Why?
|
| Oxygen | 1 | 2010 | 745 | 0.060 |
Why?
|
| Pyrimidine Nucleotides | 2 | 1995 | 7 | 0.060 |
Why?
|
| Lesch-Nyhan Syndrome | 9 | 1987 | 9 | 0.060 |
Why?
|
| Consensus | 1 | 2007 | 366 | 0.060 |
Why?
|
| Decision Making | 1 | 2011 | 669 | 0.060 |
Why?
|
| Nucleic Acid Hybridization | 2 | 1999 | 243 | 0.060 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2005 | 90 | 0.060 |
Why?
|
| Cognition | 1 | 2010 | 579 | 0.060 |
Why?
|
| Analysis of Variance | 2 | 2004 | 899 | 0.060 |
Why?
|
| Evidence-Based Medicine | 1 | 2008 | 434 | 0.060 |
Why?
|
| Trypsin | 2 | 2002 | 95 | 0.060 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2005 | 111 | 0.060 |
Why?
|
| Drug Therapy, Combination | 3 | 2019 | 785 | 0.060 |
Why?
|
| Milk | 1 | 2005 | 53 | 0.060 |
Why?
|
| Physical Examination | 1 | 2005 | 149 | 0.060 |
Why?
|
| Joints | 3 | 2011 | 32 | 0.060 |
Why?
|
| Syndrome | 2 | 2003 | 450 | 0.060 |
Why?
|
| Patient Education as Topic | 1 | 2008 | 364 | 0.060 |
Why?
|
| Ribonucleotides | 2 | 1984 | 13 | 0.060 |
Why?
|
| Clinical Enzyme Tests | 1 | 1984 | 7 | 0.060 |
Why?
|
| Enzyme Activation | 5 | 1989 | 696 | 0.060 |
Why?
|
| Aminoimidazole Carboxamide | 1 | 1984 | 7 | 0.060 |
Why?
|
| Insurance Claim Review | 1 | 2004 | 45 | 0.060 |
Why?
|
| Placebos | 1 | 2004 | 211 | 0.060 |
Why?
|
| Molecular Structure | 1 | 2005 | 293 | 0.060 |
Why?
|
| Adenosine Monophosphate | 2 | 1994 | 28 | 0.060 |
Why?
|
| Allosteric Regulation | 2 | 1999 | 67 | 0.060 |
Why?
|
| Diagnosis, Differential | 3 | 2018 | 1607 | 0.060 |
Why?
|
| Genes | 3 | 1996 | 306 | 0.060 |
Why?
|
| High-Frequency Ventilation | 2 | 2001 | 9 | 0.050 |
Why?
|
| Lupus Vulgaris | 1 | 2003 | 4 | 0.050 |
Why?
|
| Intubation, Intratracheal | 2 | 2002 | 147 | 0.050 |
Why?
|
| Hematopoietic Stem Cells | 1 | 1985 | 305 | 0.050 |
Why?
|
| Immunoglobulin G | 1 | 2005 | 469 | 0.050 |
Why?
|
| Imidazoles | 1 | 1984 | 140 | 0.050 |
Why?
|
| Aza Compounds | 1 | 2003 | 8 | 0.050 |
Why?
|
| Antibodies, Antinuclear | 2 | 2017 | 84 | 0.050 |
Why?
|
| Mitogens | 1 | 1983 | 62 | 0.050 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2003 | 28 | 0.050 |
Why?
|
| Family Practice | 1 | 2023 | 83 | 0.050 |
Why?
|
| Prevalence | 2 | 2018 | 1250 | 0.050 |
Why?
|
| Factor Xa Inhibitors | 1 | 2003 | 23 | 0.050 |
Why?
|
| Diet | 1 | 2006 | 444 | 0.050 |
Why?
|
| Gene Expression Regulation | 1 | 2011 | 1983 | 0.050 |
Why?
|
| Infant Care | 1 | 2002 | 6 | 0.050 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 1994 | 315 | 0.050 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2005 | 346 | 0.050 |
Why?
|
| Airway Resistance | 1 | 2002 | 70 | 0.050 |
Why?
|
| Feedback | 3 | 1995 | 134 | 0.050 |
Why?
|
| Respiratory Function Tests | 3 | 2004 | 140 | 0.050 |
Why?
|
| Cluster Analysis | 2 | 2014 | 371 | 0.050 |
Why?
|
| Fluorescein Angiography | 1 | 2002 | 96 | 0.050 |
Why?
|
| RNA, Messenger | 2 | 1999 | 2025 | 0.050 |
Why?
|
| Maximum Tolerated Dose | 2 | 2013 | 263 | 0.050 |
Why?
|
| Indoles | 1 | 2003 | 300 | 0.050 |
Why?
|
| Catalysis | 3 | 1986 | 205 | 0.050 |
Why?
|
| Interprofessional Relations | 1 | 2021 | 121 | 0.050 |
Why?
|
| Radioimmunoassay | 3 | 1986 | 155 | 0.050 |
Why?
|
| Positive-Pressure Respiration | 1 | 2001 | 40 | 0.050 |
Why?
|
| Guanine | 3 | 1977 | 207 | 0.050 |
Why?
|
| Patient Transfer | 1 | 2021 | 99 | 0.050 |
Why?
|
| Sulfonamides | 1 | 2003 | 319 | 0.040 |
Why?
|
| Bacillus subtilis | 1 | 2001 | 89 | 0.040 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2001 | 418 | 0.040 |
Why?
|
| Consolidation Chemotherapy | 1 | 2020 | 23 | 0.040 |
Why?
|
| Combined Modality Therapy | 2 | 2016 | 1704 | 0.040 |
Why?
|
| Guanosine Diphosphate | 2 | 1993 | 19 | 0.040 |
Why?
|
| Non-Randomized Controlled Trials as Topic | 1 | 2019 | 6 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2010 | 2676 | 0.040 |
Why?
|
| Maintenance Chemotherapy | 1 | 2020 | 84 | 0.040 |
Why?
|
| Amidophosphoribosyltransferase | 1 | 1979 | 1 | 0.040 |
Why?
|
| Nasopharyngitis | 1 | 2019 | 2 | 0.040 |
Why?
|
| Adenine | 6 | 1983 | 88 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2014 | 840 | 0.040 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2019 | 16 | 0.040 |
Why?
|
| Alanine Transaminase | 1 | 2019 | 72 | 0.040 |
Why?
|
| Aspartate Aminotransferases | 1 | 2019 | 75 | 0.040 |
Why?
|
| Naproxen | 1 | 2019 | 14 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2006 | 2392 | 0.040 |
Why?
|
| Hybrid Cells | 3 | 1992 | 71 | 0.040 |
Why?
|
| Cough | 1 | 2019 | 55 | 0.040 |
Why?
|
| Disease Progression | 2 | 2018 | 1469 | 0.040 |
Why?
|
| Headache | 1 | 2019 | 73 | 0.040 |
Why?
|
| Molecular Weight | 4 | 1984 | 331 | 0.040 |
Why?
|
| Models, Biological | 3 | 2001 | 1765 | 0.040 |
Why?
|
| Magnesium | 4 | 1984 | 178 | 0.040 |
Why?
|
| Mortality | 1 | 2019 | 149 | 0.040 |
Why?
|
| Respiration Disorders | 1 | 1998 | 41 | 0.040 |
Why?
|
| Niridazole | 1 | 1977 | 1 | 0.040 |
Why?
|
| Germany | 1 | 2018 | 73 | 0.040 |
Why?
|
| Dexamethasone | 1 | 2020 | 343 | 0.040 |
Why?
|
| Respiratory Tract Infections | 1 | 2019 | 107 | 0.040 |
Why?
|
| Cell Division | 3 | 1989 | 692 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2023 | 798 | 0.040 |
Why?
|
| Diarrhea | 1 | 2019 | 178 | 0.040 |
Why?
|
| Adenine Nucleotides | 2 | 2014 | 63 | 0.040 |
Why?
|
| Macromolecular Substances | 4 | 1988 | 177 | 0.040 |
Why?
|
| Pandemics | 1 | 2023 | 778 | 0.040 |
Why?
|
| Early Diagnosis | 1 | 2018 | 126 | 0.040 |
Why?
|
| Computer Simulation | 1 | 2021 | 1101 | 0.040 |
Why?
|
| Pain Measurement | 2 | 2011 | 332 | 0.040 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 2017 | 24 | 0.040 |
Why?
|
| Early Medical Intervention | 1 | 2017 | 20 | 0.040 |
Why?
|
| Liver Transplantation | 1 | 2004 | 1175 | 0.040 |
Why?
|
| Cricetinae | 2 | 1990 | 558 | 0.030 |
Why?
|
| Cause of Death | 1 | 2018 | 269 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 1 | 2018 | 151 | 0.030 |
Why?
|
| Spondylitis, Ankylosing | 1 | 1976 | 25 | 0.030 |
Why?
|
| Mediastinal Emphysema | 1 | 1996 | 6 | 0.030 |
Why?
|
| Crohn Disease | 1 | 2003 | 764 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2019 | 345 | 0.030 |
Why?
|
| New York | 1 | 2016 | 73 | 0.030 |
Why?
|
| Chromatography, Ion Exchange | 1 | 1996 | 34 | 0.030 |
Why?
|
| Europe | 1 | 2017 | 324 | 0.030 |
Why?
|
| Oxypurinol | 1 | 1975 | 2 | 0.030 |
Why?
|
| Cell Survival | 2 | 2014 | 983 | 0.030 |
Why?
|
| Hip Joint | 1 | 1976 | 54 | 0.030 |
Why?
|
| Autoantibodies | 1 | 2017 | 270 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2014 | 952 | 0.030 |
Why?
|
| DNA Primers | 1 | 1996 | 543 | 0.030 |
Why?
|
| Heterozygote | 3 | 2002 | 373 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2019 | 351 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2011 | 2018 | 0.030 |
Why?
|
| Hemolysis | 3 | 1984 | 64 | 0.030 |
Why?
|
| Intermittent Positive-Pressure Ventilation | 1 | 1994 | 3 | 0.030 |
Why?
|
| Metabolic Diseases | 2 | 2012 | 50 | 0.030 |
Why?
|
| Age of Onset | 2 | 2008 | 319 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2019 | 1864 | 0.030 |
Why?
|
| Time-to-Treatment | 1 | 2016 | 124 | 0.030 |
Why?
|
| Lethal Dose 50 | 1 | 2014 | 8 | 0.030 |
Why?
|
| Bronchopulmonary Dysplasia | 1 | 1994 | 43 | 0.030 |
Why?
|
| Glycine | 5 | 1976 | 95 | 0.030 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 2 | 1 | 2014 | 6 | 0.030 |
Why?
|
| Blotting, Southern | 2 | 1992 | 127 | 0.030 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2014 | 171 | 0.030 |
Why?
|
| Adenylate Kinase | 1 | 1994 | 13 | 0.030 |
Why?
|
| Dinucleoside Phosphates | 1 | 1994 | 12 | 0.030 |
Why?
|
| Spectrum Analysis, Raman | 1 | 2013 | 15 | 0.030 |
Why?
|
| Ventilator Weaning | 1 | 1994 | 24 | 0.030 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2014 | 47 | 0.030 |
Why?
|
| Logistic Models | 1 | 2018 | 1214 | 0.030 |
Why?
|
| Spectrophotometry | 1 | 1994 | 108 | 0.030 |
Why?
|
| Febrile Neutropenia | 1 | 2014 | 16 | 0.030 |
Why?
|
| Substrate Specificity | 2 | 1985 | 352 | 0.030 |
Why?
|
| Caspases | 1 | 2014 | 155 | 0.030 |
Why?
|
| Arabinonucleosides | 1 | 2014 | 39 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2014 | 198 | 0.030 |
Why?
|
| Drug Administration Routes | 1 | 2013 | 19 | 0.030 |
Why?
|
| Host-Parasite Interactions | 1 | 2013 | 30 | 0.030 |
Why?
|
| Hematologic Diseases | 1 | 2014 | 78 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2000 | 1452 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2014 | 259 | 0.030 |
Why?
|
| Family | 1 | 1995 | 325 | 0.030 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2014 | 65 | 0.030 |
Why?
|
| Tacrolimus | 2 | 2005 | 369 | 0.030 |
Why?
|
| Gene Frequency | 2 | 2008 | 687 | 0.030 |
Why?
|
| Methylene Blue | 3 | 1979 | 18 | 0.030 |
Why?
|
| Hospitalization | 1 | 2019 | 886 | 0.030 |
Why?
|
| Enzyme Stability | 1 | 1993 | 39 | 0.030 |
Why?
|
| Thioguanine | 2 | 1989 | 17 | 0.030 |
Why?
|
| Incidence | 1 | 2018 | 1600 | 0.030 |
Why?
|
| Plant Roots | 1 | 2013 | 107 | 0.030 |
Why?
|
| Restriction Mapping | 1 | 1993 | 154 | 0.030 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2015 | 101 | 0.030 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1993 | 125 | 0.030 |
Why?
|
| Algorithms | 2 | 2011 | 1908 | 0.030 |
Why?
|
| Glutamine | 3 | 1987 | 79 | 0.030 |
Why?
|
| Ultraviolet Rays | 1 | 2013 | 195 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2014 | 181 | 0.030 |
Why?
|
| Probability | 2 | 2004 | 350 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2013 | 315 | 0.030 |
Why?
|
| Plasmids | 1 | 1993 | 291 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2014 | 484 | 0.030 |
Why?
|
| Cerebrospinal Fluid Proteins | 1 | 2012 | 9 | 0.030 |
Why?
|
| Lung Diseases, Interstitial | 1 | 1996 | 262 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2014 | 1048 | 0.030 |
Why?
|
| Thrombocytopenia | 1 | 2013 | 187 | 0.030 |
Why?
|
| Risk | 1 | 2014 | 657 | 0.030 |
Why?
|
| Peptides | 2 | 2011 | 649 | 0.030 |
Why?
|
| Arylsulfatases | 1 | 1992 | 2 | 0.030 |
Why?
|
| Aminopterin | 1 | 1992 | 5 | 0.030 |
Why?
|
| DNA Polymerase II | 1 | 1992 | 9 | 0.030 |
Why?
|
| Hypoxia | 1 | 1997 | 657 | 0.030 |
Why?
|
| Dosage Compensation, Genetic | 1 | 1992 | 17 | 0.030 |
Why?
|
| Discriminant Analysis | 1 | 2012 | 67 | 0.030 |
Why?
|
| Cloning, Molecular | 1 | 1993 | 645 | 0.020 |
Why?
|
| Thermodynamics | 1 | 1993 | 314 | 0.020 |
Why?
|
| Sugar Phosphates | 2 | 1981 | 8 | 0.020 |
Why?
|
| Homozygote | 2 | 2002 | 201 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1993 | 503 | 0.020 |
Why?
|
| Gluconates | 2 | 1981 | 13 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 2014 | 334 | 0.020 |
Why?
|
| Leeches | 1 | 2011 | 5 | 0.020 |
Why?
|
| Injections, Intra-Arterial | 1 | 2011 | 32 | 0.020 |
Why?
|
| Rats | 2 | 2011 | 4048 | 0.020 |
Why?
|
| Adenine Phosphoribosyltransferase | 2 | 1984 | 2 | 0.020 |
Why?
|
| Genetic Variation | 1 | 1998 | 1380 | 0.020 |
Why?
|
| Respiratory Insufficiency | 1 | 1993 | 162 | 0.020 |
Why?
|
| Mucositis | 1 | 2010 | 17 | 0.020 |
Why?
|
| Pancytopenia | 1 | 2010 | 23 | 0.020 |
Why?
|
| Carmustine | 1 | 2010 | 70 | 0.020 |
Why?
|
| Medical Records | 1 | 2011 | 120 | 0.020 |
Why?
|
| Cricetulus | 1 | 1990 | 127 | 0.020 |
Why?
|
| Melphalan | 1 | 2010 | 98 | 0.020 |
Why?
|
| Heart Arrest | 1 | 2014 | 278 | 0.020 |
Why?
|
| Health Surveys | 1 | 2011 | 240 | 0.020 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2010 | 65 | 0.020 |
Why?
|
| Illinois | 1 | 2012 | 485 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 1993 | 869 | 0.020 |
Why?
|
| Protein Conformation | 3 | 1977 | 895 | 0.020 |
Why?
|
| Etoposide | 1 | 2010 | 206 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2010 | 387 | 0.020 |
Why?
|
| Bicarbonates | 2 | 1979 | 58 | 0.020 |
Why?
|
| Heart Conduction System | 1 | 2010 | 112 | 0.020 |
Why?
|
| Structure-Activity Relationship | 2 | 2003 | 414 | 0.020 |
Why?
|
| Azaserine | 2 | 1987 | 4 | 0.020 |
Why?
|
| Central Nervous System Diseases | 1 | 1989 | 52 | 0.020 |
Why?
|
| Sjogren's Syndrome | 1 | 1989 | 34 | 0.020 |
Why?
|
| Patient Participation | 1 | 2011 | 226 | 0.020 |
Why?
|
| Transcriptome | 1 | 2014 | 661 | 0.020 |
Why?
|
| Echocardiography, Doppler | 1 | 2010 | 187 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2011 | 785 | 0.020 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 2008 | 28 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2011 | 720 | 0.020 |
Why?
|
| Cladribine | 1 | 2008 | 35 | 0.020 |
Why?
|
| Blast Crisis | 1 | 2008 | 37 | 0.020 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2009 | 166 | 0.020 |
Why?
|
| Imatinib Mesylate | 1 | 2008 | 126 | 0.020 |
Why?
|
| In Vitro Techniques | 2 | 2003 | 996 | 0.020 |
Why?
|
| Hemoglobin, Sickle | 1 | 1988 | 19 | 0.020 |
Why?
|
| Computational Biology | 1 | 2011 | 551 | 0.020 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2008 | 166 | 0.020 |
Why?
|
| Birth Weight | 2 | 1998 | 148 | 0.020 |
Why?
|
| Diphosphoglyceric Acids | 2 | 1977 | 10 | 0.020 |
Why?
|
| Benzamides | 1 | 2008 | 234 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2007 | 103 | 0.020 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2011 | 663 | 0.020 |
Why?
|
| Software | 1 | 2011 | 669 | 0.020 |
Why?
|
| Gestational Age | 2 | 1998 | 329 | 0.020 |
Why?
|
| International Cooperation | 1 | 2007 | 127 | 0.020 |
Why?
|
| Phosphoric Acids | 4 | 1974 | 5 | 0.020 |
Why?
|
| Bone Marrow | 1 | 2008 | 443 | 0.020 |
Why?
|
| RNA | 1 | 1991 | 583 | 0.020 |
Why?
|
| Exons | 1 | 2008 | 453 | 0.020 |
Why?
|
| Carbon Isotopes | 4 | 1973 | 74 | 0.020 |
Why?
|
| Cross Reactions | 2 | 1984 | 109 | 0.020 |
Why?
|
| Atrial Fibrillation | 1 | 2010 | 357 | 0.020 |
Why?
|
| Etanercept | 1 | 2005 | 33 | 0.020 |
Why?
|
| Gadolinium | 1 | 2006 | 103 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2005 | 43 | 0.020 |
Why?
|
| Guanine Nucleotides | 2 | 1977 | 14 | 0.020 |
Why?
|
| Carbon Radioisotopes | 3 | 1974 | 35 | 0.020 |
Why?
|
| Electrophoresis | 3 | 1974 | 55 | 0.020 |
Why?
|
| Crystallization | 1 | 2005 | 215 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2011 | 1255 | 0.020 |
Why?
|
| Emulsions | 1 | 2004 | 19 | 0.010 |
Why?
|
| Heart Ventricles | 1 | 2010 | 786 | 0.010 |
Why?
|
| Glucose | 2 | 1979 | 629 | 0.010 |
Why?
|
| Radiochemistry | 1 | 1984 | 5 | 0.010 |
Why?
|
| Dialysis | 1 | 1984 | 24 | 0.010 |
Why?
|
| Patient Selection | 1 | 2008 | 682 | 0.010 |
Why?
|
| Pain | 1 | 2007 | 399 | 0.010 |
Why?
|
| Monocytes | 1 | 1986 | 221 | 0.010 |
Why?
|
| Radiography | 2 | 1996 | 808 | 0.010 |
Why?
|
| Ribonucleosides | 1 | 1984 | 25 | 0.010 |
Why?
|
| Azathioprine | 1 | 2004 | 124 | 0.010 |
Why?
|
| Mice | 3 | 1990 | 11846 | 0.010 |
Why?
|
| Xerophthalmia | 1 | 2003 | 1 | 0.010 |
Why?
|
| Cyclosporine | 1 | 2004 | 238 | 0.010 |
Why?
|
| Antigens, CD20 | 1 | 2003 | 35 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2003 | 76 | 0.010 |
Why?
|
| Genes, Dominant | 1 | 2003 | 117 | 0.010 |
Why?
|
| Purine Nucleosides | 1 | 1983 | 7 | 0.010 |
Why?
|
| Tritium | 1 | 1983 | 133 | 0.010 |
Why?
|
| Biopsy | 1 | 1987 | 1184 | 0.010 |
Why?
|
| Microsomes, Liver | 1 | 2003 | 49 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 2003 | 122 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2011 | 2649 | 0.010 |
Why?
|
| Uridine | 1 | 1983 | 56 | 0.010 |
Why?
|
| Rituximab | 1 | 2003 | 117 | 0.010 |
Why?
|
| Trypsinogen | 1 | 2002 | 4 | 0.010 |
Why?
|
| Guanosine | 1 | 1983 | 30 | 0.010 |
Why?
|
| Biological Availability | 1 | 2003 | 91 | 0.010 |
Why?
|
| Equipment Safety | 1 | 2002 | 33 | 0.010 |
Why?
|
| Embryo, Mammalian | 1 | 1983 | 223 | 0.010 |
Why?
|
| Infliximab | 1 | 2003 | 159 | 0.010 |
Why?
|
| India | 1 | 2002 | 125 | 0.010 |
Why?
|
| Family Health | 1 | 2002 | 162 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2002 | 221 | 0.010 |
Why?
|
| Formates | 2 | 1979 | 7 | 0.010 |
Why?
|
| Biological Products | 1 | 2004 | 158 | 0.010 |
Why?
|
| Dogs | 1 | 2003 | 706 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2005 | 700 | 0.010 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2002 | 73 | 0.010 |
Why?
|
| Phenotype | 1 | 2008 | 2450 | 0.010 |
Why?
|
| Ligands | 1 | 2003 | 447 | 0.010 |
Why?
|
| Crystallography, X-Ray | 1 | 2003 | 490 | 0.010 |
Why?
|
| Phosphorylation | 1 | 1984 | 1130 | 0.010 |
Why?
|
| Equipment Design | 1 | 2002 | 422 | 0.010 |
Why?
|
| Brain | 1 | 2011 | 2303 | 0.010 |
Why?
|
| Contrast Media | 1 | 2006 | 1084 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 1981 | 388 | 0.010 |
Why?
|
| Carbamyl Phosphate | 1 | 1979 | 2 | 0.010 |
Why?
|
| Clone Cells | 2 | 1978 | 214 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2010 | 2301 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2008 | 2360 | 0.010 |
Why?
|
| 6-Aminonicotinamide | 1 | 1979 | 1 | 0.010 |
Why?
|
| Critical Care | 1 | 2002 | 384 | 0.010 |
Why?
|
| Graft Rejection | 1 | 2004 | 1076 | 0.010 |
Why?
|
| Isoelectric Point | 1 | 1978 | 16 | 0.010 |
Why?
|
| Clinical Protocols | 1 | 1998 | 158 | 0.010 |
Why?
|
| Depression, Chemical | 1 | 1977 | 27 | 0.010 |
Why?
|
| Echoencephalography | 1 | 1997 | 12 | 0.010 |
Why?
|
| Insulin | 1 | 1983 | 1148 | 0.010 |
Why?
|
| Catalase | 1 | 1977 | 49 | 0.010 |
Why?
|
| Administration, Inhalation | 1 | 1997 | 192 | 0.010 |
Why?
|
| Azaguanine | 1 | 1977 | 1 | 0.010 |
Why?
|
| Oxygen Consumption | 1 | 1997 | 245 | 0.010 |
Why?
|
| Joint Prosthesis | 1 | 1976 | 26 | 0.010 |
Why?
|
| Amino Acids | 1 | 1977 | 246 | 0.010 |
Why?
|
| Rabbits | 2 | 1976 | 640 | 0.010 |
Why?
|
| Infant, Very Low Birth Weight | 1 | 1996 | 52 | 0.010 |
Why?
|
| Cellulose | 2 | 1974 | 57 | 0.010 |
Why?
|
| Osteoarthritis | 1 | 1976 | 75 | 0.010 |
Why?
|
| Protein Denaturation | 1 | 1975 | 106 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 1996 | 296 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2002 | 744 | 0.010 |
Why?
|
| Allosteric Site | 1 | 1995 | 22 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 1977 | 463 | 0.010 |
Why?
|
| Hot Temperature | 1 | 1975 | 207 | 0.010 |
Why?
|
| Orotic Acid | 1 | 1974 | 5 | 0.010 |
Why?
|
| Glutathione Reductase | 1 | 1974 | 7 | 0.010 |
Why?
|
| Glucosephosphate Dehydrogenase | 1 | 1974 | 18 | 0.010 |
Why?
|
| Binding Sites | 1 | 1977 | 1121 | 0.010 |
Why?
|
| Immunodiffusion | 1 | 1973 | 28 | 0.010 |
Why?
|
| Radioisotopes | 1 | 1973 | 43 | 0.010 |
Why?
|
| Lithium | 1 | 1973 | 62 | 0.010 |
Why?
|
| Immunoassay | 1 | 1973 | 91 | 0.010 |
Why?
|
| Nitrogen | 1 | 1973 | 73 | 0.010 |
Why?
|
| Nucleotides | 1 | 1973 | 98 | 0.010 |
Why?
|
| Nicotinic Acids | 1 | 1972 | 8 | 0.010 |
Why?
|
| Steryl-Sulfatase | 1 | 1992 | 1 | 0.010 |
Why?
|
| Zinc Fingers | 1 | 1992 | 58 | 0.010 |
Why?
|
| DNA Probes | 1 | 1992 | 77 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1992 | 258 | 0.010 |
Why?
|
| Pneumonia | 1 | 1993 | 183 | 0.010 |
Why?
|
| Neuroblastoma | 1 | 1973 | 400 | 0.010 |
Why?
|
| Xanthines | 1 | 1989 | 3 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 1988 | 511 | 0.000 |
Why?
|
| Polymers | 1 | 1988 | 196 | 0.000 |
Why?
|
| Chromatography, Thin Layer | 2 | 1973 | 32 | 0.000 |
Why?
|
| Immunoelectrophoresis | 1 | 1976 | 19 | 0.000 |
Why?
|
| Precipitin Tests | 1 | 1976 | 111 | 0.000 |
Why?
|
| Antigens | 1 | 1976 | 229 | 0.000 |
Why?
|
| Lipidoses | 1 | 1974 | 4 | 0.000 |
Why?
|
| Chromatography, DEAE-Cellulose | 1 | 1974 | 20 | 0.000 |
Why?
|
| Phosphorus Radioisotopes | 1 | 1974 | 19 | 0.000 |
Why?
|
| Methods | 1 | 1974 | 151 | 0.000 |
Why?
|
| Indicators and Reagents | 1 | 1974 | 72 | 0.000 |
Why?
|
| Evaluation Studies as Topic | 1 | 1974 | 270 | 0.000 |
Why?
|
| Diploidy | 1 | 1973 | 31 | 0.000 |
Why?
|
| Diphosphates | 1 | 1972 | 18 | 0.000 |
Why?
|
| Ribose | 1 | 1972 | 17 | 0.000 |
Why?
|